MARYLENE D.

MULLASGO

TTH (1:00 PM 4:00 PM)

BSA 4D
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
Valeant Pharmaceuticals International, Inc. is established in Laval, Quebec, Canada.
The said company mainly manufactures generic pharmaceuticals and over-the-counter
products. It focuses in dermatology, eye health, aesthetics, consumer products, gastrointestinal,
oral health, neurology and other therapeutic areas. Because of its success, the company was
able to buy Bausch & Lomb which is one of the well-known manufacturers of contact lenses.
It was J. Michael Pearson who made the continuous growth of Valeant improved,
through a series of mergers and acquisitions. Nevertheless, during 2015 2016, the company
was involved in a controversy about drug price hikes and the use of a specialty pharmacy for
the distribution of its specialty drugs.
The following are the companys major prescription drugs:

Acne drugs, namely, Solodyn, Ziana, Acanya, Atralin

Retin-A Micro, Microsphere, ONEXTON Gel
Wellbutrin XL for treatment of depression
Jublia for treatment of toenail fungus
Targretin, a retinoid for treatment of Cutaneous TCell
Lymphoma
Arestin an antibiotic used for procedures related to periodontitis
Zovirax a topical antiviral used against herpes viruses
Syprine used for treatment of patients with Wilsons disease
Elidel used to treat atopic dermatitis

On the other hand, the companys major over the counter drugs are as follows:

PreserVision, an eye vitamin

CeraVe, for skin treatment
ReNu Multiplus, for lubrication of contact lenses
Biotrue, an eye lubricant
Ocuvite, an eye vitamin
Boston, for cleaning of contact lenses
Artelac, to treat dry eyes

An important part of the growth strategy for Valeant has been acquisitions of medical
and pharmaceutical companies and subsequent price increases for their products. As a result of
this strategy, smaller pharmaceutical companies refocused away from research and

development towards serial acquisitions of existing technologies, more aggressive marketing

and rapid price increases to enhance growth. In September 2015, an influential group of
politicians criticized Valeant on its pricing strategies.[72] The company raised prices on all its
brand name drugs 66% in 2015, five times more than its closest industry peer.
In addition, on October 21, 2015, Citron Research, controlled by Andrew Left, a short
seller of Valeant shares, claimed that Valeant recorded false sales of products to specialty
pharmacy Philidor Rx Services and its affiliates. These specialty pharma companies were
controlled by Valeant and allegedly resulted in the improper booking of revenue.